TPX-0046
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TPX-0046, covering 2024-06-13 to 2024-06-13. Get the full timeline:
Most recent: Clinical Trial Update: Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations [Phase 1, Phase 2]